Medical Licensing (MD/DO) · Independent exam preparation
ABFM Family Medicine Certification Examination: Clinical Decisions Guide Study Guide
Practise diagnostic thresholds, safe treatment changes, emergency priorities and US screening decisions across ABFM's five domains, with cases and explanations.
By CertMedbry · Updated 19 October 2026
Practise deciding when to test, when to treat, when to escalate care and how to monitor treatment safely. This guide develops those decisions through 60 selected concepts, clinical mini-cases, 20 independent questions and 20 recall cards. It addresses the American Board of Family Medicine's Family Medicine Certification Examination, commonly called the one-day exam. The current official blueprint defines the full scope; these clinical selections do not exhaust its breadth across ages, maternity care, mental health, surgical care and community practice. Screening recommendations are explicitly attributed to the US Preventive Services Task Force where applicable.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Which examination and certification pathway does this guide address?
The selected assessment is ABFM's one-day Family Medicine Certification Examination. The 2026 booklet states that initial and continuing certification candidates take the same examination. ABFM is the awarding board; specialty certification and medical licensure have separate requirements. Eligibility through residency, entry, re-entry or reciprocity does not create a different examination within this guide.
2026 Family Medicine Certification Examination Information Booklet
How many questions are presented, and how many are scored or pretest?
ABFM specifies 300 single-best-answer multiple-choice questions, divided into four sections of 75. Its one-day examination format page does not specify how many questions are scored or designated as pretest; a numerical breakdown is therefore not stated here.
How long is the examination?
Each of the four sections lasts 95 minutes, giving 380 minutes of question time. Candidates have 100 minutes of pooled break time available between sections. These figures describe section and break allowances; they do not establish a complete appointment duration including registration and orientation.
How is the examination delivered, and can answers be reviewed?
The examination is computer based at Prometric test centers. Within the active section, candidates can navigate, mark questions and change answers before time expires. A completed or expired section cannot be reopened.
Which item styles should candidates expect?
ABFM identifies clinical scenarios using single-best-answer multiple-choice questions. Its tutorial may demonstrate other formats, but the one-day examination uses only this specified format. The questions here are independent educational drills and provide no prediction of examination performance.
ABFM One-Day Exam · 2026 Family Medicine Certification Examination Information Booklet
Which blueprint applies, and when did it become effective?
The clinical-activity blueprint became effective January 1, 2025, and is confirmed for the 2026 examination. Target percentages are Acute Care and Diagnosis 35%, Chronic Care Management 25%, Emergent and Urgent Care 20%, Preventive Care 15%, and Foundations of Care 5%. This replaces the earlier organ-system organization.
ABFM Family Medicine Exam Blueprint · New in 2025: Redesigned Family Medicine Exam Blueprint · 2026 Family Medicine Certification Examination Information Booklet
Are longitudinal assessment and the In-Training Exam other names for this examination?
No. Family Medicine Certification Longitudinal Assessment and the resident In-Training Exam are separate assessments that share the blueprint. This guide addresses the one-day examination; its section timing and review rules should not be applied to those separate assessments.
ABFM Family Medicine Exam Blueprint · 2026 Family Medicine Certification Examination Information Booklet
How should the guide's clinical coverage be used?
Use these selections to practise decision making, then use the official blueprint and booklet as the full scope reference. The examination spans family medicine across the lifespan. This guide includes selected adolescent and neonatal feeding decisions and foundational applications in statistics, vaccination law and equitable access to screening. These examples remain selective rather than comprehensive.
ABFM Family Medicine Exam Blueprint · 2026 Family Medicine Certification Examination Information Booklet
This is independent preparation for physician specialty board certification through ABFM. Concepts follow the current clinical-activity domains: 21 acute, 15 chronic, 12 urgent/emergent, nine preventive and three foundational. Questions and cards each follow the corresponding 7/5/4/3/1 distribution. Clinical recommendations are supported by their cited clinical authorities; the ABFM outline establishes examination scope.
Outline used: Current five-domain blueprint effective January 1, 2025, confirmed in the officially linked 2026 Family Medicine Certification Examination Information Booklet, filename version v.1.0. Reviewed for October 10, 2026, Asia/Hong_Kong. The workbook label 'American Board of Family Medicine' names the awarding board; it maps here to its Family Medicine Certification Examination (one-day exam). The assigned slug is preserved.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Acute Care and Diagnosis35%
1.When does a sore throat need streptococcal testing?
Clear viral features such as cough, rhinorrhea, hoarseness, oral ulcers or conjunctivitis support viral pharyngitis and usually remove the need for group A streptococcal testing. Without those features, examination alone cannot reliably distinguish streptococcal from viral infection. Testing therefore resolves a treatment decision rather than merely confirming an impression. A positive rapid antigen test or throat culture supports antibiotic treatment; tonsillar exudate alone does not establish the cause.
Apply it
A 19-year-old has sore throat, cough, rhinorrhea and conjunctivitis after household cold exposure. Explain why the viral pattern supports symptomatic care without streptococcal testing, despite mild tonsillar erythema on examination today.
Common pitfall: Exudate and throat redness are tempting shortcuts to antibiotics. Neither overrides a clear viral syndrome or independently establishes a bacterial cause of pharyngitis.
2.Why does a negative rapid strep test mean different things in children and adults?
Rapid antigen tests are highly specific but have variable sensitivity, so a negative result can miss infection. In symptomatic children aged three years or older, obtain a backup throat culture and arrange communication of positive results. This protects against missed streptococcal disease and its rheumatic fever risk. Adults do not routinely need culture confirmation after a negative rapid antigen test because acute rheumatic fever is very rare in that population.
Apply it
An eight-year-old has fever, tender anterior cervical nodes and sore throat without cough. The rapid antigen test is negative. Send a throat culture and arrange to contact the family if antibiotics become indicated.
Common pitfall: Applying the adult testing pathway to schoolchildren can miss treatable infection. Conversely, routinely culturing every adult negative rapid test adds testing without the same expected benefit.
3.Which antibiotic best fits confirmed streptococcal pharyngitis?
Penicillin or amoxicillin is preferred for confirmed group A streptococcal pharyngitis when allergy does not preclude use. Their reliable activity permits focused treatment without unnecessary broader coverage. Allergy history matters: cephalexin and cefadroxil should be avoided in immediate penicillin hypersensitivity. Macrolide and clindamycin resistance varies geographically and over time, whereas clinical resistance to penicillin has not been reported. Oral penicillin and amoxicillin regimens generally require ten days.
Apply it
A healthy adult has a positive rapid streptococcal test and no drug allergies. Choose penicillin or amoxicillin rather than automatically selecting azithromycin for convenience, and discuss completing the recommended treatment course as prescribed.
Common pitfall: A shorter or broader regimen is not automatically better. Distinguish immediate hypersensitivity from a nonspecific historical intolerance before choosing an alternative antibiotic.
4.Which symptom patterns support acute bacterial rhinosinusitis?
CDC describes three supporting patterns: persistent symptoms for more than ten days without improvement; severe symptoms lasting more than 3–4 days, with fever at least 39°C and purulent nasal discharge or facial pain; or worsening symptoms over 3–4 days after initial improvement of a viral illness lasting about 5–6 days. The trajectory is more discriminating than discharge color alone. Most acute rhinosinusitis is viral, and routine sinus radiographs are not recommended for uncomplicated presentations.
Apply it
An adult's congestion improves after five days, then new fever and facial pain develop with worsening discharge over the next four days. Recognize the worsening trajectory as evidence supporting bacterial rhinosinusitis rather than an uninterrupted cold.
Common pitfall: Green discharge during an otherwise improving four-day illness is insufficient evidence for bacterial sinusitis. A low-grade fever alone also does not satisfy the separate severe-course criterion.
5.When is observation reasonable for uncomplicated bacterial sinusitis?
The 2025 AAO-HNSF guideline recommends offering watchful waiting for uncomplicated adult bacterial rhinosinusitis when follow-up is assured. Establish reassessment within 3–5 days after diagnosis and earlier for worsening at any time; absent improvement or worsening should prompt reassessment and antibiotic initiation if uncomplicated bacterial sinusitis remains the diagnosis. This differs from antibiotic treatment failure: failure to improve or worsening despite 3–5 days of an appropriate antibiotic requires confirmation of the diagnosis, exclusion of other causes and complications, and an antibiotic change if bacterial sinusitis is confirmed.
Apply it
A stable adult has twelve days of symptoms without improvement and no complication signs. Agree on symptomatic treatment and contact within 3–5 days, with immediate review for worsening. Start antibiotics if observation fails and reassessment still supports uncomplicated bacterial sinusitis.
Common pitfall: Do not restart an observation interval in someone already failing an appropriate antibiotic. Orbital or neurologic findings require urgent complication assessment rather than routine outpatient rescue treatment.
CDC Outpatient Clinical Care for Adults · CPG_ASU_SummaryGuide_V3.pdf · CPG-AdultSinusitisUpdate_Flowchart_V13.pdf
6.Which antibiotic choices fit adult bacterial sinusitis?
When antibiotics are selected for adult bacterial rhinosinusitis, amoxicillin or amoxicillin-clavulanate is first-line therapy in CDC guidance. The 2025 AAO-HNSF guideline recommends 5–7 days for most adults. Azithromycin is a poor routine substitute because pneumococcal resistance limits reliability. CDC alternatives for appropriate penicillin-allergic adults include doxycycline or a respiratory fluoroquinolone. Selection must incorporate allergy phenotype and patient context. A convenient dosing schedule does not compensate for inadequate expected activity.
Apply it
A nonpregnant adult with bacterial sinusitis requires antibiotics and reports immediate penicillin anaphylaxis. Review an appropriate non-beta-lactam alternative such as doxycycline, accounting for contraindications, rather than defaulting to azithromycin because it was previously prescribed.
Common pitfall: Do not generalize adult alternatives to pregnant patients or children. Antibiotic suitability depends on the patient's circumstances as well as the diagnostic label.
CDC Outpatient Clinical Care for Adults · CPG_ASU_SummaryGuide_V3.pdf
7.What ear findings establish acute otitis media?
Acute otitis media requires middle-ear effusion plus appropriate acute inflammatory findings. Moderate or severe tympanic membrane bulging, or new otorrhea unrelated to otitis externa, strongly supports the diagnosis. Mild bulging requires recent ear pain or intense erythema. Pneumatic otoscopy or tympanometry helps establish effusion. Ear tugging and a red membrane alone are insufficient because they do not establish infected fluid in the middle-ear space during the current illness.
Apply it
A crying toddler has a red tympanic membrane but normal mobility and no bulging or effusion. Reconsider acute otitis media rather than prescribing antibiotics solely for redness observed during a distressed examination in clinic.
Common pitfall: Middle-ear fluid without the required acute inflammatory findings is not automatically acute otitis media. Diagnostic precision prevents antibiotics for redness or effusion alone.
8.When can a child with acute otitis media be observed?
For uncomplicated acute otitis media without otorrhea, nonsevere symptoms mean mild otalgia lasting less than 48 hours and temperature below 39°C. Observation with shared decision making and assured follow-up is an option for unilateral disease at 6–23 months and unilateral or bilateral disease at 24 months or older. Bilateral disease at 6–23 months, otorrhea, or severe symptoms favor antibiotics. Severe symptoms include moderate or severe otalgia, otalgia lasting at least 48 hours, or temperature at least 39°C. Begin antibiotics if worsening occurs at any time or improvement fails within 48–72 hours.
Apply it
A four-year-old has bilateral acute otitis media without otorrhea, mild pain for eighteen hours and temperature 38.2°C. Offer analgesia and observation with a reliable 48–72-hour rescue plan. A twenty-month-old with the same bilateral findings should receive antibiotics.
Common pitfall: Bilateral disease has a different treatment implication below age two. Observation requires both nonsevere symptoms and an actual mechanism to start antibiotics if the child worsens or fails to improve.
CDC Outpatient Clinical Care for Pediatric Populations · oma_aap_2013.pdf
9.When should otitis media treatment include clavulanate?
Amoxicillin is the usual first-line antibiotic for acute otitis media when there has been no recent amoxicillin exposure and no modifying feature. Amoxicillin-clavulanate is preferred when amoxicillin was used within the preceding thirty days, concurrent purulent conjunctivitis is present, or recurrent disease has not responded to amoxicillin. These cues change the expected coverage requirement. Broader treatment should follow a specific reason rather than the assumption that all ear infections need it.
Apply it
A child with definite acute otitis media also has purulent conjunctivitis and no penicillin allergy. Select amoxicillin-clavulanate when antibiotic treatment is indicated, using the accompanying eye findings to guide the coverage decision in this episode.
Common pitfall: Prior success with plain amoxicillin does not erase current modifying features. Conversely, uncomplicated first episodes do not routinely require broader therapy merely to appear stronger.
10.When should pelvic inflammatory disease receive empiric treatment?
Use a low threshold for empiric pelvic inflammatory disease treatment in a sexually active patient at STI risk who has pelvic or lower abdominal pain, no better identified cause, and cervical motion, uterine or adnexal tenderness. One qualifying tenderness finding is sufficient. Negative cervical gonorrhea and chlamydia tests do not exclude upper genital tract infection. Conversely, normal cervical discharge and no vaginal white cells make PID less likely. Assess pregnancy and alternative emergencies while making the treatment decision.
Apply it
A 23-year-old with a new partner has pelvic pain, mucopurulent discharge and cervical motion tenderness. Pregnancy testing is negative and no surgical cause is identified. Begin empiric PID treatment while obtaining appropriate STI testing.
Common pitfall: Waiting for all three tenderness findings or a positive cervical test sacrifices sensitivity. Empiric treatment does not remove the need to assess competing emergencies.
11.How should adolescent age influence the PID disposition decision?
Adolescent age alone does not justify hospitalization for PID: CDC reports similar outpatient responses in younger and older patients. Apply the same admission criteria, including pregnancy, tubo-ovarian abscess, severe illness, an unexcluded surgical emergency, inability to follow or tolerate oral treatment, or failure of outpatient therapy. An outpatient adolescent needs a feasible medication and follow-up plan, with clinical improvement within 72 hours. Assess actual treatment feasibility rather than assuming either reliable adherence or inevitable failure from age.
Apply it
A nonpregnant seventeen-year-old with mild PID tolerates medication, has no abscess or surgical concern and can return for review. Outpatient treatment is reasonable. If vomiting prevents oral treatment, admit on that clinical basis rather than on age alone.
Common pitfall: Automatic admission based on adolescence and automatic discharge based on mild pain both miss the relevant criteria. Severity, competing diagnoses and the ability to complete treatment determine disposition.
12.Why does outpatient PID treatment use multiple antibiotics?
PID treatment must cover gonorrhea, chlamydia and relevant anaerobes because the syndrome is polymicrobial. A recommended outpatient combination uses ceftriaxone with doxycycline and metronidazole in an appropriate nonpregnant patient. The components address different coverage needs; symptomatic improvement after one drug does not demonstrate eradication of the full infection. Negative cervical screening does not justify omitting gonorrhea or chlamydia coverage when the clinical diagnosis remains PID and treatment is indicated.
Apply it
A stable, nonpregnant adult with mild PID can take oral medications and return for review. Explain why ceftriaxone plus doxycycline and metronidazole provides complementary coverage, instead of treating the syndrome with metronidazole alone for associated vaginal odor.
Common pitfall: Treating accompanying bacterial vaginosis alone leaves major PID pathogens uncovered. The outpatient regimen is a coordinated combination, not a menu of interchangeable single agents.
13.Which findings change PID disposition or follow-up?
Hospitalization is appropriate when pregnancy, tubo-ovarian abscess, severe illness, inability to tolerate outpatient therapy or an unexcluded surgical emergency changes the risk. Outpatients should show clinical improvement within seventy-two hours. Failure to improve requires reassessment, additional diagnostics and escalation rather than simply extending the same plan. Disposition reflects disease severity and the feasibility of effective treatment; adolescent age alone does not establish a need for admission in otherwise suitable patients.
Apply it
A patient treated for PID returns after three days with unchanged pain and fever despite taking the regimen. Reassess the diagnosis and complications and arrange hospital-level evaluation, rather than renewing the same outpatient prescriptions without further investigation.
Common pitfall: A completed prescription is not evidence of clinical response. Persistent symptoms at the reassessment boundary require investigation for complications, inadequate treatment or an alternative diagnosis.
14.Which positional finding identifies posterior canal BPPV?
Posterior canal benign paroxysmal positional vertigo is supported when Dix-Hallpike positioning provokes vertigo with torsional, upbeating nystagmus. The reproducible positional response localizes the problem more specifically than the word dizziness. If the history fits but testing shows horizontal or no nystagmus, a supine roll test assesses lateral canal disease. Atypical neurologic findings or a different symptom pattern require reconsideration rather than automatic assignment of every positional complaint to posterior canal BPPV.
Apply it
A patient experiences brief spinning when rolling in bed. Dix-Hallpike testing produces torsional, upbeating nystagmus on the symptomatic side. Use this reproducible finding to identify posterior canal BPPV and choose a targeted management approach.
Common pitfall: A history of dizziness with movement alone is insufficient localization. Interpret the provoked eye movement pattern and evaluate findings that do not fit the expected syndrome.
15.How should typical posterior canal BPPV be treated and reassessed?
Treat posterior canal benign paroxysmal positional vertigo with a canalith repositioning procedure, which moves displaced particles out of the affected semicircular canal. Routine vestibular suppressants do not correct this mechanical cause. Imaging is unnecessary when diagnostic criteria are met and no inconsistent findings suggest another disorder. Reassess within one month after treatment or observation to document resolution or persistence, even when symptoms appear to have improved. Evaluate persistent symptoms for unresolved BPPV and other peripheral vestibular or central nervous system disorders.
Apply it
An older adult with characteristic posterior canal BPPV and no focal neurologic findings receives repositioning treatment. Discuss fall precautions, assess available support, and arrange reassessment within one month. If positional episodes persist, reevaluate for unresolved BPPV; if the symptom pattern changes, assess for an additional diagnosis. Concerning changes, such as new focal neurologic findings, require earlier evaluation.
Common pitfall: Do not make follow-up conditional on persistent symptoms or leave its timing unspecified. Improvement should be documented at reassessment within one month. Persistent dizziness should prompt diagnostic reevaluation rather than repeated prescriptions for sedating vestibular suppressants.
16.What combination of findings supports bacterial vaginosis?
Bacterial vaginosis reflects a shift in vaginal microbial composition rather than a diagnosis made from odor alone. Amsel diagnosis requires at least three of four findings: homogeneous thin discharge, clue cells, vaginal pH above 4.5 and a fishy odor with or without potassium hydroxide. Clue cells are epithelial cells coated by adherent bacteria. Vaginal Gram stain with Nugent scoring is another established approach. Molecular tests are intended for symptomatic patients; cervical cytology and Gardnerella culture are unsuitable diagnostic substitutes.
Apply it
A patient has thin homogeneous discharge, vaginal pH 5.2 and clue cells on microscopy, without a documented whiff test. Recognize that three qualifying findings satisfy Amsel criteria. An incidental Pap report suggesting BV in an asymptomatic patient does not establish symptomatic disease.
Common pitfall: An elevated pH alone does not identify bacterial vaginosis. Requiring all four Amsel findings is unnecessarily strict, while relying on cervical cytology uses a test with poor diagnostic utility for BV.
17.How should neonatal feeding be planned during maternal metronidazole treatment?
For a breastfeeding parent treated for symptomatic BV, CDC considers lower-dose metronidazole regimens compatible with breastfeeding. Milk transfers drug and its active metabolite, but infant exposure is below doses used to treat infant infections. Distinguish a standard divided-dose course from a single 2-g maternal dose, after which some clinicians recommend a 12–24-hour breastfeeding interruption.
Apply it
A healthy two-week-old is breastfed while the parent receives metronidazole 500 mg twice daily for seven days. Continue breastfeeding rather than automatically interrupting neonatal feeds because the medication enters milk.
Common pitfall: Milk transfer alone does not establish harmful exposure. Do not apply advice about a single 2-g dose indiscriminately to a lower-dose treatment course or to other drugs.
18.When should suspected influenza in pregnancy be treated?
Pregnancy increases the risk of influenza complications, so suspected influenza warrants prompt antiviral treatment without waiting for laboratory confirmation. Treatment is recommended in any trimester and through two weeks postpartum, including after pregnancy loss. A negative rapid influenza test does not reliably exclude infection. The decision combines the clinical syndrome and community influenza activity, because delaying treatment to obtain certainty can reduce the benefit of early therapy in a higher-risk patient.
Apply it
A patient at twenty-four weeks' gestation develops abrupt fever, cough and myalgias during a local influenza surge. Start empiric antiviral treatment while arranging appropriate evaluation, despite a negative rapid antigen result obtained earlier that day.
Common pitfall: A negative rapid test should not overrule a convincing syndrome in pregnancy. Waiting for confirmation can turn a timely treatment decision into an avoidable delay.
CDC Antiviral Recommendations for Obstetric Health Care Providers
19.Which antiviral and timing principles apply to obstetric influenza?
Oral oseltamivir is the preferred influenza treatment during pregnancy because the available safety and benefit evidence is most substantial for this agent. Benefit is greatest when treatment begins early, but hospitalized or severely ill patients may still benefit after forty-eight hours. Baloxavir is not recommended during pregnancy or breastfeeding because relevant safety and efficacy data are lacking. A timing threshold should therefore guide urgency without becoming an automatic exclusion from treatment.
Apply it
A pregnant patient is hospitalized on the fourth day of influenza-like illness with worsening respiratory symptoms. Begin oseltamivir rather than withholding treatment because the usual early-treatment window has passed, while assessing severity and other care needs.
Common pitfall: The greatest-benefit window is not an absolute stopping rule for severe illness. Approval for influenza treatment in general does not establish suitability during pregnancy or breastfeeding.
CDC Antiviral Recommendations for Obstetric Health Care Providers
20.How does uncomplicated bronchitis differ from suspected pneumonia?
Evaluation of acute cough should first look for pneumonia rather than use sputum color to decide on antibiotics. In otherwise healthy adults, normal vital signs and the absence of focal consolidation findings make pneumonia less likely. Abnormal temperature, respiratory rate, pulse or focal lung findings change that assessment. Routine antibiotics do not benefit uncomplicated acute bronchitis regardless of cough duration. Persistent cough alone therefore does not convert a viral bronchitic illness into bacterial pneumonia.
Apply it
A healthy adult has a week of cough with green sputum, normal temperature, pulse and respiratory rate, and no focal lung findings. Explain why supportive treatment is appropriate rather than antibiotics based on sputum color alone.
Common pitfall: Colored sputum is not a bacterial test. Equally, a bronchitis label should not suppress further pneumonia assessment when abnormal vital signs or focal findings are present.
21.Which patients fit the uncomplicated cystitis treatment framework?
The uncomplicated cystitis framework applies to otherwise healthy, nonpregnant, premenopausal women with a compatible lower urinary tract syndrome. Dysuria, urgency and frequent small-volume voiding support that syndrome, with nitrites and leukocyte esterase providing useful urinary evidence. Nitrofurantoin and fosfomycin are first-line options; empiric trimethoprim-sulfamethoxazole is also appropriate where local resistance is below 20%. Fluoroquinolones are generally reserved when other agents are unsuitable. Patient category and evidence of illness beyond the bladder change the framework.
Apply it
A healthy nonpregnant woman has dysuria, frequency and nitrite-positive urine without systemic illness. If local resistance is 25%, choose a suitable alternative such as nitrofurantoin or fosfomycin rather than empiric trimethoprim-sulfamethoxazole.
Common pitfall: The resistance threshold is below 20%, not merely a favorable-sounding local pattern. Do not transfer this narrow treatment framework automatically to pregnancy, men or systemic infection.
Chronic Care Management25%
22.Why must CKD assessment include albuminuria as well as filtration?
Estimated glomerular filtration rate and urine albumin-to-creatinine ratio describe different dimensions of chronic kidney disease. Filtration estimates kidney clearance, whereas albuminuria indicates kidney damage and contributes additional prognostic information. Persistent abnormalities over at least three months support chronicity. Combining these measures guides risk assessment and treatment selection more effectively than creatinine alone. A preserved filtration estimate does not exclude clinically important kidney disease when persistent albuminuria demonstrates an abnormality of kidney structure or function.
Apply it
A patient has eGFR 78 mL/min/1.73 m² and urine albumin-to-creatinine ratio 420 mg/g on repeated measurements over four months. Recognize clinically important albuminuric CKD despite filtration that might otherwise appear reassuring on its own.
Common pitfall: One abnormal result does not establish chronicity. Conversely, an eGFR above 60 does not erase persistent albuminuria or eliminate its implications for treatment and prognosis.
KDIGO 2024 Clinical Practice Guideline for Chronic Kidney Disease
23.How should renin-angiotensin system blockade be monitored in CKD?
An ACE inhibitor or ARB can reduce albuminuric kidney risk, but initiation or dose escalation requires monitoring blood pressure, creatinine and potassium within two to four weeks. These drugs alter glomerular hemodynamics and potassium handling, so laboratory change must be interpreted rather than ignored. Use the highest tolerated approved dose when indicated. Combining an ACE inhibitor with an ARB or direct renin inhibitor adds harm and is not an acceptable strategy for greater kidney protection.
Apply it
A patient with albuminuric CKD starts an ARB and remains clinically stable. Arrange blood pressure, creatinine and potassium review within two to four weeks, including repeat monitoring after later dose increases rather than waiting for routine annual laboratories.
Common pitfall: Good blood pressure control does not prove laboratory safety. Dual renin-angiotensin blockade is a tempting intensification strategy but should not replace appropriate single-agent titration.
KDIGO 2024 Clinical Practice Guideline for Chronic Kidney Disease
24.When does a creatinine increase require reassessing ACE inhibitor or ARB therapy?
A modest creatinine increase after ACE inhibitor or ARB initiation can reflect the expected hemodynamic effect rather than progressive kidney injury. KDIGO advises continuing unless creatinine rises by more than thirty percent within four weeks, while also considering symptoms and potassium. A larger rise prompts assessment for reversible contributors and treatment adjustment. Hyperkalemia can often be managed without immediately abandoning therapy. The percentage change and clinical context are more useful than any increase alone.
Apply it
Creatinine rises from 1.0 to 1.2 mg/dL two weeks after starting an ARB; potassium and blood pressure are acceptable. Calculate a twenty percent rise and continue monitored therapy rather than automatically discontinuing a potentially protective medication.
Common pitfall: The thirty percent boundary is not permission to ignore severe hyperkalemia or symptomatic hypotension. Laboratory percentages must be interpreted alongside other clinically important safety findings.
KDIGO 2024 Clinical Practice Guideline for Chronic Kidney Disease
25.Which CKD patients benefit from SGLT2 inhibition beyond glucose lowering?
SGLT2 inhibitors provide kidney and cardiovascular protection in qualifying CKD patients, including some without diabetes. KDIGO recommends treatment for adults with eGFR at least 20 mL/min/1.73 m² and urine albumin-to-creatinine ratio at least 200 mg/g, or heart failure irrespective of albuminuria. An initial reversible filtration decline is generally not a reason to stop. Temporary withholding during prolonged fasting, surgery or critical illness addresses increased ketosis risk under those conditions.
Apply it
An adult without diabetes has eGFR 38 mL/min/1.73 m² and persistent albumin-to-creatinine ratio 650 mg/g. Discuss SGLT2 treatment for organ protection, including temporary interruption during prolonged fasting or major acute illness when ketosis risk rises.
Common pitfall: A normal glucose level does not remove the kidney indication. Likewise, the expected early eGFR dip should not automatically be interpreted as drug-induced progressive kidney failure.
KDIGO 2024 Clinical Practice Guideline for Chronic Kidney Disease
26.Which treatment classes form the foundation of chronic HFrEF care?
Chronic heart failure with reduced ejection fraction requires disease-modifying therapy rather than symptom control alone. Core classes include renin-angiotensin system inhibition, preferably an appropriate ARNI, an evidence-based beta blocker, a mineralocorticoid receptor antagonist and an SGLT2 inhibitor. Each addresses an important component of disease progression. Diuretics relieve congestion but do not substitute for this foundation. Choice and titration depend on blood pressure, kidney function, potassium and tolerance rather than a single uniform prescription.
Apply it
A stable patient with LVEF 30% takes only a loop diuretic and reports less edema. Review opportunities to introduce the major disease-modifying classes, checking blood pressure, kidney function and potassium instead of equating symptom relief with complete treatment.
Common pitfall: A dry examination does not mean HFrEF therapy is complete. Congestion relief and modification of future hospitalization or mortality risk are related but different treatment goals.
27.Why are SGLT2 inhibitors used in HFrEF without diabetes?
The heart failure indication for SGLT2 inhibitors does not depend on diabetes. In symptomatic chronic HFrEF, these agents reduce heart failure hospitalization and cardiovascular mortality regardless of type 2 diabetes status. Their role therefore extends beyond lowering blood glucose. Candidate assessment still includes kidney function, volume status and relevant safety considerations. The discriminating clinical feature is qualifying heart failure, not an elevated hemoglobin A1c or a need for another glucose-lowering drug.
Apply it
A patient with symptomatic chronic HFrEF has normal A1c and suitable kidney function. Explain that an SGLT2 inhibitor is being considered for heart failure outcomes, so absence of diabetes does not remove the treatment rationale.
Common pitfall: Classifying every drug solely by its original indication can hide later organ-protection evidence. Normal glycemia does not establish that an SGLT2 inhibitor lacks benefit in HFrEF.
28.When should heart failure therapy continue after ejection fraction improves?
Improvement from a previous LVEF of 40% or less to a later value above 40% identifies heart failure with improved ejection fraction. This improvement may reflect successful treatment rather than permanent elimination of the underlying vulnerability. Continue guideline-directed therapy to prevent recurrent ventricular dysfunction and heart failure, even when symptoms resolve. The historical low ejection fraction remains important; interpreting only the most recent measurement can lead to withdrawal of the therapy maintaining recovery.
Apply it
A patient's LVEF improves from 28% to 52% on treatment and exercise tolerance normalizes. Continue tolerated disease-modifying therapy and explain relapse prevention rather than stopping medications solely because the latest echocardiogram appears normal and symptoms have resolved.
Common pitfall: Recovered measurements do not prove that treatment is unnecessary. Distinguish improvement maintained by therapy from a demonstrated absence of the condition that originally required treatment.
29.When is long-term urate lowering indicated, and how is allopurinol started safely?
Strong indications for urate lowering include tophi, gout-related radiographic damage or frequent flares, defined as at least two annually. Allopurinol is preferred first-line, including in CKD: start at no more than 100 mg/day, with a lower starting dose in CKD, then titrate. ACR conditionally recommends pretreatment HLA-B*58:01 testing for patients of Southeast Asian descent, including Han Chinese, Korean and Thai ancestry, and for African American patients because the allele increases severe hypersensitivity risk. Routine universal testing is conditionally discouraged in other groups.
Apply it
A patient of Han Chinese ancestry has three gout flares annually and CKD. Discuss HLA-B*58:01 testing before allopurinol, a starting dose below the usual 100 mg/day ceiling because of CKD, and subsequent monitored titration.
Common pitfall: A low starting dose is not the final urate target. Selected-population HLA testing should neither be omitted in the recommended groups nor presented as mandatory universal screening.
2020 American College of Rheumatology Guideline for the Management of Gout
30.How is urate-lowering therapy titrated to a meaningful target?
Use serial serum urate measurements to titrate urate-lowering therapy toward a sustained level below 6 mg/dL. A fixed starting dose may be inadequate, so clinical success cannot be inferred from prescription completion alone. Lowering urate reduces the conditions supporting crystal deposition and permits gradual reduction of crystal burden. Absence of a recent flare does not prove the biochemical target has been reached. Review adherence, tolerance and the measured response before deciding whether adjustment is needed.
Apply it
A patient takes allopurinol consistently but serum urate remains 8.1 mg/dL. Review tolerance and titrate appropriately with repeat measurements, rather than leaving the starting dose unchanged because no flare occurred during the preceding month.
Common pitfall: The initial low dose is a safety strategy, not the final treatment target. Short-term freedom from pain can coexist with persistent urate supersaturation and ongoing crystal burden.
2020 American College of Rheumatology Guideline for the Management of Gout
31.Why is flare prophylaxis needed when urate lowering begins?
Starting urate-lowering therapy can temporarily provoke flares even though its long-term purpose is to reduce them. Concomitant anti-inflammatory prophylaxis helps bridge this period, usually for at least three to six months with reassessment if flares continue. Colchicine, an NSAID or a glucocorticoid may be selected according to patient factors. Prophylaxis and urate lowering have different jobs: one suppresses inflammation during transition, while the other reduces the underlying crystal burden over time.
Apply it
A patient with recurrent gout starts allopurinol and develops an early flare. Treat the inflammatory episode and review prophylaxis rather than declaring urate lowering ineffective simply because symptoms occurred soon after treatment initiation this month.
Common pitfall: A flare soon after initiation does not show failure of the long-term strategy. Anti-inflammatory prophylaxis also does not replace titration toward the serum urate target.
2020 American College of Rheumatology Guideline for the Management of Gout
32.Why screen for bipolar disorder before prescribing sertraline?
A depressive presentation can occur within bipolar disorder, and antidepressant treatment can precipitate mania or hypomania in a susceptible patient. Before sertraline, assess personal and family histories of bipolar disorder and episodes of elevated or irritable mood with increased activity. Reduced need for sleep and unusually risky behavior are useful discriminating historical clues. The goal is to identify a different longitudinal illness pattern before treating the current symptoms as unipolar depression alone.
Apply it
A patient requesting treatment for depression recalls a previous week of little sleep, excessive spending and unusually high energy without fatigue. Clarify that history and assess for bipolar disorder before initiating sertraline as routine unipolar depression treatment.
Common pitfall: Current low mood does not exclude prior mania or hypomania. Asking only whether the patient has previously received a bipolar diagnosis misses clinically important undiagnosed episodes.
33.How can abrupt sertraline cessation be distinguished from depressive relapse?
Abrupt discontinuation of sertraline can produce dizziness, nausea, sensory disturbances, anxiety, irritability and sleep symptoms. A close temporal relationship to stopping or sharply reducing medication, especially with electric shock-like sensations, supports discontinuation syndrome. Gradual dose reduction is recommended when stopping treatment when feasible. Relapse assessment remains important, but new physical symptoms immediately following cessation should not automatically be labeled recurrent depression or proof that the underlying disorder has suddenly worsened.
Apply it
A patient abruptly stops long-term sertraline and soon develops dizziness, nausea and electric shock-like sensations. Recognize a discontinuation pattern, review the medication change and develop an individualized management and tapering plan rather than diagnosing relapse from these symptoms alone.
Common pitfall: Discontinuation symptoms and relapse can overlap. The timing and sensory symptoms guide interpretation, but neither should eliminate assessment of mood, safety and the broader clinical course.
34.Which medication combinations increase bleeding concerns with sertraline?
Sertraline and other serotonin reuptake inhibitors can increase bleeding risk, and concomitant aspirin, NSAIDs, antiplatelet drugs or anticoagulants may add to that risk. Medication review should therefore include nonprescription analgesics, not just psychiatric prescriptions. The combination is not automatically forbidden, but its indication, alternatives and signs of bleeding deserve attention. New bruising or gastrointestinal bleeding symptoms should prompt assessment rather than being dismissed as unrelated to a medication that primarily treats mood symptoms.
Apply it
A patient taking sertraline begins frequent over-the-counter ibuprofen while also receiving an anticoagulant. Review the added bleeding risk and pain-treatment alternatives, and assess any new bruising or gastrointestinal symptoms instead of assuming nonprescription use is inconsequential.
Common pitfall: A medication can affect systems beyond its primary indication. Missing over-the-counter NSAIDs during reconciliation can conceal a clinically important combination even when prescribed drugs are documented.
35.When is a bisphosphonate holiday appropriate?
Reassess fracture risk after three to five years of bisphosphonate treatment rather than applying an automatic stopping date. Patients who remain at high risk generally continue therapy, while those at low-to-moderate risk may be considered for a monitored holiday. Bisphosphonate effects can persist after cessation, which supports this selective approach. A new fracture or meaningful decline in bone density during a holiday may justify restarting treatment before the initially planned end of the interruption.
Apply it
A postmenopausal patient completes five years of oral bisphosphonate treatment. Review interval fractures, bone density and current risk before deciding between continued treatment and a monitored holiday, rather than stopping solely because five years have elapsed.
Common pitfall: Elapsed treatment time alone does not establish low fracture risk. A holiday requires reassessment and a plan for restarting treatment if the patient's risk increases.
36.Why does denosumab require a planned transition when stopped?
Denosumab's suppression of bone turnover reverses when scheduled treatment is interrupted. Stopping or delaying it without subsequent therapy can produce rebound turnover, rapid bone loss and increased fracture risk. This differs from the residual skeletal effect that can support selected bisphosphonate holidays. If denosumab must be discontinued, arrange an appropriate subsequent osteoporosis treatment rather than leaving an unprotected gap. An improved bone density measurement does not remove the need for this transition.
Apply it
A patient with improved bone density wants to stop denosumab because injections are inconvenient. Explain the rebound risk and arrange a suitable transition to another osteoporosis therapy rather than simply cancelling the next scheduled injection without replacement.
Common pitfall: Do not extend the bisphosphonate holiday concept to denosumab. Similar fracture-prevention goals do not mean these drugs have interchangeable persistence after treatment stops.
Emergent and Urgent Care20%
37.Which findings demand recognition of anaphylaxis?
Anaphylaxis is a clinical emergency suggested by rapid progression after an exposure with respiratory compromise, circulatory compromise or a compatible combination of systemic manifestations. Hives and angioedema are common but may be absent, so their absence cannot exclude the diagnosis. Wheeze, stridor, hypotension and collapse are especially concerning. The management decision must follow the dangerous physiology rather than wait for a complete rash, laboratory confirmation or a perfectly documented exposure history before treatment begins.
Apply it
Minutes after vaccination, an adult develops wheezing, throat tightness and hypotension without hives. Recognize anaphylaxis and initiate emergency treatment rather than waiting for skin changes to confirm the suspected systemic reaction in this rapidly deteriorating patient.
Common pitfall: Requiring urticaria misses some severe reactions. Isolated itching and life-threatening airway or circulatory compromise also require different levels of urgency and should not be conflated.
38.Why is intramuscular epinephrine the first treatment for anaphylaxis?
For adults, give epinephrine 0.3–0.5 mg IM using the 1 mg/mL preparation in the mid-outer thigh; repeat every 5–15 minutes as needed. Alpha-adrenergic vasoconstriction supports perfusion and reduces mucosal edema; beta-adrenergic effects support cardiac function and bronchodilation. Activate emergency support simultaneously. Antihistamines cannot replace epinephrine, and anaphylaxis has no absolute contraindication to its use.
Apply it
An older adult with coronary disease develops stridor, wheeze and hypotension after an injection. Give IM epinephrine promptly despite the cardiac history, while arranging resuscitation support.
Common pitfall: Do not confuse the 1 mg/mL IM preparation with a diluted infusion. Treating itching first leaves airway compromise and shock inadequately treated.
39.How should persistent anaphylaxis be escalated after initial epinephrine?
For persistent adult symptoms, repeat epinephrine 0.3–0.5 mg IM from the 1 mg/mL preparation every 5–15 minutes as clinically needed. Reassess airway, breathing and circulation and give IV crystalloid for hypotension. Refractory symptoms despite IM doses and fluids may require a titrated epinephrine infusion with continuous monitoring and experienced support; infusion escalation is distinct from initial IM treatment.
Apply it
An adult remains hypotensive and wheezy after the first IM dose. Repeat epinephrine at the appropriate interval, provide fluids and escalate monitored care.
Common pitfall: One dose does not establish adequate response. An improvised IV epinephrine bolus is not a substitute for controlled infusion escalation.
40.What three components establish adult diabetic ketoacidosis?
The 2024 consensus requires diabetes or glucose at least 200 mg/dL, significant ketosis and metabolic acidosis for DKA. Significant blood beta-hydroxybutyrate is at least 3 mmol/L; acidosis is indicated by pH below 7.3 or bicarbonate below 18 mmol/L. In a patient with known diabetes, glucose need not be markedly elevated. The combination identifies insulin-deficient ketone production with acid accumulation, rather than treating hyperglycemia alone as synonymous with ketoacidosis.
Apply it
An adult with known diabetes has glucose 185 mg/dL, beta-hydroxybutyrate 5 mmol/L and venous pH 7.24. Recognize DKA from the diabetes history, ketosis and acidosis despite glucose below the usual image of a hyperglycemic emergency.
Common pitfall: A glucose threshold alone cannot diagnose or exclude DKA. Hyperglycemia without ketosis and acidosis is a different problem, while known diabetes can permit a lower-glucose presentation.
Hyperglycaemic Crises in Adults With Diabetes: A Consensus Report
41.When should near-normal glucose raise concern for euglycemic DKA?
SGLT2 inhibitor exposure, reduced intake, pregnancy and other settings can permit DKA with glucose below 200 mg/dL. The glucose value may appear reassuring while ketone production and acidosis remain dangerous. In a compatible illness with nausea, vomiting, abdominal symptoms or abnormal breathing, assess ketones and acid-base status. Recognizing the medication and physiologic context prevents dismissal of DKA solely because the patient lacks the marked hyperglycemia often associated with the diagnosis.
Apply it
A patient taking an SGLT2 inhibitor develops vomiting and deep breathing after several days of poor intake. Glucose is 170 mg/dL. Obtain blood ketones and acid-base testing urgently instead of attributing the illness to a minor gastrointestinal infection.
Common pitfall: SGLT2-associated glucose lowering can obscure a familiar diagnostic cue. A relatively normal glucose reading is insufficient reassurance when symptoms suggest ketone-related metabolic illness.
Hyperglycaemic Crises in Adults With Diabetes: A Consensus Report
42.Why is blood beta-hydroxybutyrate preferred for DKA assessment?
Beta-hydroxybutyrate is the principal ketoacid in DKA, whereas common nitroprusside urine tests detect acetoacetate. This mismatch can underestimate early ketosis and exaggerate apparent persistence during recovery as beta-hydroxybutyrate converts to acetoacetate. Direct blood measurement therefore better supports diagnosis and response monitoring. Urine ketones can still provide information when blood testing is unavailable, but their biochemical limitation must shape interpretation rather than being mistaken for a precise real-time measure of disease severity.
Apply it
A treated DKA patient is improving, but urine ketones remain prominent while blood beta-hydroxybutyrate falls. Use the blood ketone trend with acid-base findings to assess recovery instead of interpreting persistent urine positivity as proof of worsening ketoacidosis.
Common pitfall: Different ketone tests measure different compounds. Treating their results as interchangeable can misclassify both the beginning of DKA and the biochemical changes during successful treatment.
Hyperglycaemic Crises in Adults With Diabetes: A Consensus Report
43.When must potassium replacement precede insulin in DKA?
DKA can deplete total-body potassium even when the initial serum concentration is normal or high. Insulin then shifts potassium into cells and may expose a dangerous deficit. The 2024 consensus recommends delaying insulin when potassium is below 3.5 mmol/L until replacement raises it above that level. This sequencing prevents life-threatening hypokalemia while fluids and close monitoring continue. Treating the metabolic disorder safely therefore requires considering electrolyte movement, not merely the need to lower glucose.
Apply it
An adult with DKA has potassium 3.1 mmol/L before insulin treatment. Begin appropriate potassium replacement with fluids and monitoring, delaying insulin until potassium exceeds 3.5 mmol/L rather than starting insulin immediately because ketones are markedly elevated.
Common pitfall: Urgency to stop ketogenesis does not justify ignoring severe potassium depletion. A high glucose value does not determine whether insulin can safely begin before electrolyte correction.
Hyperglycaemic Crises in Adults With Diabetes: A Consensus Report
44.How is DKA resolution distinguished from glucose normalization?
Glucose often improves before ketoacidosis resolves, so dextrose may be added to permit continued insulin without hypoglycemia. Resolution requires plasma ketones below 0.6 mmol/L plus venous pH at least 7.3 or bicarbonate at least 18 mmol/L. Glucose should ideally also be below 200 mg/dL. The anion gap alone is unsuitable as the resolution criterion because treatment-related hyperchloremic acidosis can distort interpretation. Follow the remaining metabolic problem rather than stopping at a normal glucose.
Apply it
During DKA treatment, glucose falls to 190 mg/dL but beta-hydroxybutyrate remains 2.4 mmol/L and acidosis persists. Continue protocol-directed insulin with appropriate dextrose support rather than declaring recovery based only on the improved glucose measurement.
Common pitfall: Normal glucose is an intermediate treatment result, not proof that ketogenesis has stopped. Conversely, residual hyperchloremic acidosis should not automatically be mistaken for persistent ketoacidosis.
Hyperglycaemic Crises in Adults With Diabetes: A Consensus Report
45.Which revascularization strategy fits ACS with cardiogenic shock?
Acute coronary syndrome with cardiogenic shock requires emergency revascularization of the culprit vessel. The need to restore flow urgently does not mean every coronary stenosis should undergo immediate PCI. The 2025 guideline advises against routine PCI of non-infarct-related arteries during the initial procedure in this setting. Distinguish the artery responsible for the acute event from additional disease; the shock-specific procedural strategy differs from a blanket assumption that more immediate intervention must produce a better outcome.
Apply it
A patient with myocardial infarction and cardiogenic shock has one culprit occlusion and another severe nonculprit stenosis. Prioritize emergency culprit-vessel revascularization rather than routinely treating both vessels during the initial PCI solely because both lesions are severe.
Common pitfall: The shock qualifier changes the procedural decision. Do not transfer a general desire for complete revascularization into routine simultaneous nonculprit PCI during cardiogenic shock.
AHA Top Things to Know: 2025 Acute Coronary Syndromes Guideline
46.Why is radial access preferred for PCI in ACS?
For patients with acute coronary syndromes undergoing PCI, a radial approach is preferred over a femoral approach because it reduces bleeding, vascular complications and mortality. This is an access strategy within definitive coronary care, not a replacement for timely revascularization. Patient anatomy and procedural circumstances still matter. The transferable principle is that selecting how an intervention is delivered can alter important outcomes even when the target coronary lesion and intention to perform PCI remain the same.
Apply it
An adult with ACS proceeds to PCI, and either vascular access site is technically suitable. Recognize radial access as the preferred strategy under the 2025 guideline rather than assuming access choice affects comfort alone and has no outcome implications.
Common pitfall: Access-site selection is clinically consequential, but a preferred approach is not an instruction to ignore technical feasibility or the need for prompt definitive treatment.
AHA Top Things to Know: 2025 Acute Coronary Syndromes Guideline
47.Which back-pain features suggest cauda equina syndrome?
New urinary retention, saddle sensory loss, bowel dysfunction or important lower-extremity deficits with back pain raise concern for cauda equina compression. Urinary overflow incontinence can reflect a full bladder rather than preserved bladder function. The threatened structures include sacral nerve roots responsible for pelvic sensation and sphincter control. These findings change the problem from routine mechanical back pain to a time-sensitive neurologic emergency, even when the patient initially describes a familiar history of sciatica.
Apply it
A patient with worsening low-back pain reports numbness around the perineum and new difficulty initiating urination. Treat the combination as suspected cauda equina syndrome requiring emergency assessment rather than offering only another course of conservative sciatica treatment.
Common pitfall: Leakage does not exclude retention because overflow can occur. Waiting for complete paralysis or total incontinence delays action beyond earlier clinically meaningful sacral nerve warning signs.
48.How should suspected cauda equina compression be investigated?
Suspected cauda equina syndrome requires urgent imaging and surgical evaluation because persistent compression can cause lasting bladder, bowel, sensory and motor deficits. MRI evaluates the compressive lesion and associated anatomy. The diagnostic pathway must occur urgently rather than through routine outpatient imaging after a trial of analgesia. Examination findings help establish concern, but an incomplete classic presentation does not justify waiting when new sacral dysfunction or progressive neurologic deficits make compression a credible possibility.
Apply it
A patient has acute back pain, new saddle numbness and urinary retention. Arrange emergency MRI and spine surgical assessment instead of scheduling a routine lumbar radiograph or waiting several weeks to see whether physical therapy helps.
Common pitfall: Plain radiography does not adequately evaluate nerve-root compression. A routine back-pain pathway becomes inappropriate once new bladder, bowel or saddle sensory dysfunction suggests an emergency.
Preventive Care15%
49.When does USPSTF average-risk colorectal screening apply?
USPSTF recommends colorectal screening for asymptomatic average-risk adults aged forty-five through seventy-five, with selective screening from seventy-six through eighty-five based on health, prior screening and preferences. This framework does not replace diagnostic evaluation for symptoms or tailored surveillance for prior colorectal disease and hereditary syndromes. Screening seeks disease in people without a presenting suspicion; the same test may serve a different purpose when bleeding, anemia or another concerning symptom is already present.
Apply it
A healthy forty-seven-year-old without symptoms, prior polyps or a hereditary syndrome asks about colorectal prevention. Offer an appropriate screening strategy now rather than waiting until fifty, while confirming that the patient fits the average-risk population.
Common pitfall: Do not use screening intervals to postpone evaluation of symptoms. Nor should average-risk recommendations be automatically assigned to a patient with a hereditary syndrome or prior relevant disease.
50.Why must a positive FIT be followed by colonoscopy?
A positive fecal immunochemical test identifies an abnormal screening result that requires colonoscopy for the screening pathway to deliver its intended benefit. Repeating the stool test cannot reliably resolve the original abnormal result or identify its source. Blood shedding can vary over time, so a later negative result does not cancel the earlier signal. Explain the follow-up requirement when offering FIT so patients understand that a home test may lead to a necessary invasive examination.
Apply it
An asymptomatic adult's screening FIT is positive, but a second self-arranged test is negative. Recommend colonoscopy to investigate the original positive result rather than treating the later negative sample as proof that further evaluation is unnecessary.
Common pitfall: Repeating FIT after a positive result creates false reassurance. The screening sequence requires diagnostic follow-up, rather than repeated sampling until a preferred result appears.
51.How do colorectal screening intervals depend on the chosen test?
Colorectal screening effectiveness depends on completing a strategy at its recommended interval. Under USPSTF options, FIT is performed annually, whereas screening colonoscopy is generally every ten years after a normal examination in an appropriate average-risk patient. Tests differ in preparation, setting, frequency and follow-up requirements. The best practical option is one the patient can complete and repeat as required. A single negative stool test does not provide the same duration of reassurance as a normal colonoscopy.
Apply it
A patient chooses annual FIT because bowel preparation and transportation make colonoscopy difficult. Establish reminders for yearly testing and explain that any positive result still requires colonoscopy, ensuring the selected strategy remains feasible beyond the first sample.
Common pitfall: A screening choice is a longitudinal commitment. Assigning a ten-year interval to a negative FIT confuses the requirements of two distinct screening strategies.
52.Which adults meet USPSTF lung screening eligibility?
USPSTF recommends annual low-dose CT for adults aged fifty through eighty with at least twenty pack-years who currently smoke or quit within the preceding fifteen years. Pack-years equal average packs per day multiplied by years smoked, adding periods with different intensities when needed. Eligibility requires the age, exposure and smoking-recency components together. This is a US recommendation for screening; symptoms suggesting lung cancer require diagnostic evaluation rather than an eligibility calculation alone.
Apply it
A sixty-two-year-old smoked half a pack daily for forty-four years and quit eight years ago. Calculate twenty-two pack-years and recognize eligibility for a shared decision about annual low-dose CT under the specified USPSTF recommendation.
Common pitfall: Counting years smoked without intensity misclassifies exposure. Also distinguish this explicitly attributed USPSTF framework from recommendations issued by other organizations or coverage policies.
53.When should USPSTF lung screening stop?
USPSTF recommends stopping screening once fifteen years have elapsed since smoking cessation, or when a health problem substantially limits life expectancy or the ability or willingness to undergo curative lung surgery. Screening benefit depends on meaningful opportunity to act on early detection. A high lifetime exposure alone therefore does not justify indefinite imaging. Reassess eligibility over time rather than continuing annual orders automatically after the reason for potential benefit has materially changed.
Apply it
A previously eligible patient develops advanced illness and would not accept curative lung surgery. Reconsider continued screening because finding an early lesion may no longer lead to the treatment pathway required for the expected preventive benefit.
Common pitfall: Past eligibility does not establish lifelong benefit. Continuing screening without considering treatment willingness can expose patients to workup harms without a realistic route to curative care.
54.What belongs in shared decision making before lung screening?
Discuss the potential mortality benefit of low-dose CT alongside false-positive findings, incidental abnormalities, overdiagnosis, radiation exposure and possible invasive follow-up. Screening is repeated annually while eligibility continues, so the decision is more than consent to one scan. Current smokers should also receive smoking cessation intervention. Shared decision making connects the evidence to the patient's priorities and willingness to pursue evaluation; screening does not replace prevention through cessation or guarantee that cancer will be found early.
Apply it
An eligible current smoker asks whether a normal low-dose CT makes smoking safe. Explain the limits and potential harms of screening, offer cessation support and confirm willingness to pursue evaluation of abnormal findings before arranging the annual strategy.
Common pitfall: Presenting screening as a harmless reassurance scan understates downstream consequences. A normal result also cannot neutralize ongoing tobacco risk or replace a smoking cessation discussion.
55.Which adults should be screened for prediabetes under USPSTF guidance?
USPSTF recommends screening asymptomatic, nonpregnant adults aged thirty-five through seventy who have overweight or obesity. Consider earlier assessment for additional risk factors and a lower BMI threshold in Asian American adults. The recommendation targets identification of prediabetes and type 2 diabetes where follow-up can change care. A symptomatic patient needs diagnostic evaluation regardless of whether the screening age-and-BMI rule is met. Eligibility rules guide preventive services rather than limiting evaluation of suspected disease.
Apply it
A forty-two-year-old without symptoms has BMI 31 and no prior glucose testing. Offer screening now using an accepted test rather than waiting for polyuria, a family history or an older age threshold before considering diabetes risk.
Common pitfall: Screening eligibility is not a diagnostic exclusion rule. Younger or leaner patients with symptoms or important risk factors may still need evaluation outside the routine population recommendation.
USPSTF Screening for Prediabetes and Type 2 Diabetes: Recommendation Statement
56.How are glucose screening results interpreted and repeated?
Accepted screening tests include fasting plasma glucose, hemoglobin A1c and a two-hour oral glucose tolerance test. Prediabetes ranges include A1c 5.7% to 6.4% or fasting glucose 100 to 125 mg/dL. Diabetes-range results in an asymptomatic person require confirmation with repeat testing. After a normal result, screening about every three years may be reasonable, although the optimal interval is uncertain. New symptoms or a materially changed risk profile can justify earlier diagnostic reassessment.
Apply it
An asymptomatic eligible adult has a normal A1c. Explain that a roughly three-year repeat interval can be reasonable while acknowledging uncertainty, and advise earlier review if symptoms develop rather than presenting the interval as an absolute guarantee.
Common pitfall: A reasonable interval is not a prohibition on earlier testing. Likewise, one diabetes-range screening value without symptoms should not automatically be treated as a fully confirmed diagnosis.
USPSTF Screening for Prediabetes and Type 2 Diabetes: Recommendation Statement
57.Why should prediabetes identification lead to an effective intervention?
Screening has practical value when abnormal findings lead to an intervention that reduces progression to diabetes. USPSTF recommends offering or referring patients with prediabetes to effective preventive interventions. Structured lifestyle programs combine dietary change, physical activity and weight management rather than relying on a vague warning to eat better. Metformin also has preventive evidence in selected populations, but lifestyle intervention has broader demonstrated benefits. Discuss feasible participation and barriers so identification leads to action.
Apply it
A patient with A1c 6.0% works irregular shifts and cannot attend a daytime class. Seek an accessible effective prevention program and agree on practical goals rather than documenting prediabetes while offering only a generic instruction to lose weight.
Common pitfall: Naming risk without an actionable intervention weakens the purpose of screening. Program access and patient circumstances matter when translating preventive evidence into meaningful participation.
USPSTF Screening for Prediabetes and Type 2 Diabetes: Recommendation Statement
Foundations of Care5%
58.How should absolute benefit, relative benefit and NNT be interpreted together?
For an adverse outcome, absolute risk reduction equals control risk minus treated risk. Relative risk reduction equals that difference divided by control risk. Number needed to treat equals 1 divided by absolute risk reduction expressed as a proportion, rounded upward. Specify the outcome, population and follow-up period. The same relative reduction yields a larger absolute benefit at higher baseline risk, so NNT values cannot be compared meaningfully without considering those features.
Apply it
A five-year trial reduces stroke risk from 10% to 6%. ARR is 0.04, RRR is 40% and NNT is 25 for five years. With the same relative effect at a baseline risk of 2%, treated risk would be 1.2%, ARR 0.008 and NNT 125.
Common pitfall: Use proportions rather than percentage-point numbers in the reciprocal. NNT describes an average effect and does not identify which individual patient benefits.
Cochrane Handbook, Chapter 15: Interpreting Results and Drawing Conclusions
59.What legal requirements govern vaccine information before administration?
For vaccines covered by the National Childhood Vaccine Injury Act, public and private providers must give the relevant Vaccine Information Statement with each administration. Discuss benefits and risks understandably and allow questions. The federal Act does not itself require a signed consent form; state or local rules may add documentation requirements.
Apply it
Before a repeat covered vaccine dose, provide its VIS again and address questions, even if the family received one previously.
Common pitfall: Prior receipt does not satisfy the requirement for the current dose. A signature alone does not replace understandable risk communication.
60.How can a screening plan address unequal access without weakening follow-up?
Equitable screening requires matching an effective strategy to the patient's actual barriers while preserving necessary diagnostic follow-up. USPSTF notes that home FIT avoids initial bowel preparation, sedation and transportation, but requires annual completion and colonoscopy after a positive result. Colonoscopy usually requires preparation, transportation assistance and recovery time. Offer an informed choice and arrange practical support for those requirements rather than treating missed appointments as proof that a patient does not value prevention.
Apply it
An eligible patient cannot obtain an escort for screening colonoscopy. Discuss annual home FIT, confirm understanding of repeat testing and establish how transportation and scheduling support would be arranged if colonoscopy becomes necessary after a positive result.
Common pitfall: Giving everyone the same appointment can preserve an access barrier. Offering FIT as a way to avoid all future colonoscopy also misrepresents the screening pathway.
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Allocate initial study time using the official 35/25/20/15/5 domain targets, then adjust for demonstrated weaknesses.
- For ambulatory presentations, identify the finding that crosses the threshold from observation to testing or treatment, and state the rescue interval.
- For chronic therapy, connect each medication to its outcome goal, monitoring requirement and reason to continue or interrupt it.
- For emergencies, practise recognizing dangerous physiology despite misleading reassurance such as absent hives or near-normal glucose.
- For preventive care, state the recommending organization, eligible population, interval and required follow-up of an abnormal result.
- Apply foundational reasoning to treatment effects, vaccination information requirements and practical barriers to completing care.
- Extend beyond these selected clinical topics using the full ABFM outline, including broader neonatal, adolescent, maternity, surgical and community care.
A practical preparation plan
1. Build a five-domain learning map
Use the official domain descriptions to organize clinical activities. Place diagnostic uncertainty, chronic adjustment, decisions needed within hours, preventive services and foundational decisions into their respective domains.
2. Explain the decisive cue
For each concept, state the diagnostic threshold or treatment mechanism aloud. Then explain how one changed finding—age, pregnancy, symptom trajectory, laboratory value or clinical instability—would change the decision.
3. Work through the cases before reading their decisions
Identify the next action, its purpose and the most tempting alternative. For medication changes, name the follow-up laboratory or clinical finding needed to judge benefit and safety.
4. Complete and review the independent questions
Answer all twenty questions before studying explanations. Classify each error as missing knowledge, misread population, overlooked discriminator or incorrect sequencing, then revisit the relevant concept and clinical reference.
5. Rehearse thresholds with spaced recall
Use the cards for screening criteria, monitoring boundaries and emergency principles. Repeat calculations using new event rates and pack-year histories so recall includes application.
6. Expand breadth and practise section pacing
Fill gaps against the full official outline, including clinical areas beyond this selective guide. Separately practise sustained single-best-answer work using the section timing described in the format FAQs.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- ABFM One-Day Exam
- 2026 Family Medicine Certification Examination Information Booklet
- ABFM Family Medicine Exam Blueprint
- New in 2025: Redesigned Family Medicine Exam Blueprint
- CDC Clinical Guidance for Group A Streptococcal Pharyngitis
- CDC Outpatient Clinical Care for Adults
- CDC Outpatient Clinical Care for Pediatric Populations
- CDC Pelvic Inflammatory Disease Treatment Guidelines
- AAO-HNSF BPPV Guideline: Press Release and Fact Sheet
- CDC Bacterial Vaginosis Treatment Guidelines
- CDC Antiviral Recommendations for Obstetric Health Care Providers
- KDIGO 2024 Clinical Practice Guideline for Chronic Kidney Disease
- 2022 AHA/ACC/HFSA Heart Failure Guideline Slide Set
- 2020 American College of Rheumatology Guideline for the Management of Gout
- DailyMed Sertraline Tablets Prescribing Information
- Endocrine Society Osteoporosis Guideline Resources
- CDC Preventing and Managing Adverse Reactions
- Hyperglycaemic Crises in Adults With Diabetes: A Consensus Report
- AHA Top Things to Know: 2025 Acute Coronary Syndromes Guideline
- AANS Cauda Equina Syndrome
- USPSTF Colorectal Cancer Screening
- USPSTF Lung Cancer Screening
- USPSTF Screening for Prediabetes and Type 2 Diabetes: Recommendation Statement
- Cochrane Handbook, Chapter 15: Interpreting Results and Drawing Conclusions
- oma_aap_2013.pdf
- CPG_ASU_SummaryGuide_V3.pdf
- CPG-AdultSinusitisUpdate_Flowchart_V13.pdf
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.